Goldman Sachs
IPSC icon

Goldman Sachs’s Century Therapeutics IPSC Stock Holding History

Goldman Sachs’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Sell
150,433
-60,049
-29% -$137K ﹤0.01% 5889
2026
Q1 		$476K Buy
+210,482
New +$443K ﹤0.01% 5633
2025
Q4 		– Sell
-60,682
Closed -$30.2K – 6624
2025
Q3 		$30.2K Sell
60,682
-215,296
-78% -$116K ﹤0.01% 6217
2025
Q2 		$154K Buy
275,978
+96,343
+54% +$51.7K ﹤0.01% 5728
2025
Q1 		$85.5K Buy
179,635
+38,052
+27% +$28.6K ﹤0.01% 5817
2024
Q4 		$143K Buy
141,583
+33,463
+31% +$45.6K ﹤0.01% 5700
2024
Q3 		$185K Buy
108,120
+37,314
+53% +$73.1K ﹤0.01% 5480
2024
Q2 		$181K Buy
70,806
+31,523
+80% +$99.6K ﹤0.01% 5295
2024
Q1 		$164K Sell
39,283
-5,342
-12% -$22.6K ﹤0.01% 5159
2023
Q4 		$148K Sell
44,625
-3,653
-8% -$6.66K ﹤0.01% 5226
2023
Q3 		$96.6K Buy
48,278
+5,067
+12% +$13.5K ﹤0.01% 5189
2023
Q2 		$137K Sell
43,211
-9,757
-18% -$31.5K ﹤0.01% 5297
2023
Q1 		$184K Buy
52,968
+22,818
+76% +$100K ﹤0.01% 5328
2022
Q4 		$155K Buy
30,150
+9,094
+43% +$85.8K ﹤0.01% 5382
2022
Q3 		$208K Sell
21,056
-4,712
-18% -$49.6K ﹤0.01% 5462
2022
Q2 		$216K Buy
25,768
+5,022
+24% +$49.3K ﹤0.01% 5610
2022
Q1 		$261K Buy
20,746
+2,091
+11% +$27.7K ﹤0.01% 5736
2021
Q4 		$296K Buy
+18,655
New +$350K ﹤0.01% 5677
2021
Q3 		– Sell
-52,808
Closed -$1.55M – 6357
2021
Q2 		$1.55M Buy
+52,808
New +$1.34M ﹤0.01% 4420

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Goldman Sachs's IPSC Position: Q2 2026 in Review

Goldman Sachs reduced its Century Therapeutics (IPSC) stake by 29% in Q2 2026, selling an estimated $137K and leaving 150,433 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #5889.

Goldman Sachs first reported a position in IPSC in Q2 2021 and has held it in 19 quarters since. The position peaked at $1.55M in Q2 2021. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Goldman Sachs held 150,433 shares of Century Therapeutics worth $369K as of Q2 2026.
  • Goldman Sachs sold 60,049 Century Therapeutics shares in Q2 2026, an estimated $137K.
  • Century Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5889 holding.
  • Goldman Sachs first reported a position in Century Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Goldman Sachs's Century Therapeutics position peaked at $1.55M in Q2 2021.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.